NGNE

In the past six months, Neurogene's stock has been affected by several events. The company reported an earnings per share (EPS) of -$1.53 for fiscal Q2 2026, missing consensus estimates and increasing its net loss, which dampened stock sentiment. The anticipated topline data from the NGN-401 Embolden™ registrational trial was extended to the second half of 2027, introducing investor uncertainty. A public offering in July 2026 secured approximately $134.8 million, extending its cash runway into fiscal Q1 2029, but also led to short-term stock dilution. Analyst ratings in October 2026 saw JPMorgan initiate coverage with an 'Overweight' rating, while H.C. Wainwright and Canaccord lowered their price targets, and Wall Street Zen downgraded the stock to 'strong sell' despite a broader 'Buy' consensus. Additionally, Neurogene announced inducement grants under Nasdaq Listing Rule 5635(c)(4) on several dates.